Maintenance of peritoneal B-1a lymphocytes in the absence of the spleen.

Positive selection by autoantigens is believed to play an important role in the generation/maintenance of B-1a cells. Recently, it has been described that splenectomy results in the loss of an already established B-1a cell pool. To elucidate whether the spleen influences the peritoneal B-1a repertoire, we have analyzed the consequences of splenectomy in the recently established IgL-transgenic L2 mouse model. L2 mice are characterized by a severe block of B-2 development and predominance of B-1a cells, which exhibit a pronounced IgH oligoclonality, presumably due to positive selection by autoantigens. In this study, we show that, in striking contrast to splenectomized normal mice, L2 mice exhibit unchanged frequencies of peritoneal B-1a cells. The IgH repertoire of these B-1a cells, however, was severely perturbed in that the previously described predominant B-1a H chains were no longer present. The repertoire changes were partial since phosphatidylcholine-specific B-1a cells were present in similar numbers before and after splenectomy. Thus, splenic Ags appear to act as "survival factors" for major subsets of peritoneal B cells. The loss of B-1a cells in the absence of such factors is compensated by repertoire changes among B-1a cells in B cell lymphopenic L2 but not normal mice.

Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo.

Prophylactic tumor vaccination against subsequent tumor challenge depends on effective cross-priming in vivo. Professional APCs process tumor antigens from whole tumor cells and present them to CD4(+) and CD8(+) T cells. Data suggest that dendritic cells process antigens more efficiently from necrotic cells than from apoptotic cells in vitro. We compared the effect of apoptosis vs. necrosis in vivo using different tumor models (CT26, RENCA, B16 and CT26-HA). Apoptosis was induced by gamma-irradiation prior to injection and verified in vivo. Apoptotic CT26-HA, CT26-wt or RENCA prevented tumor outgrowth in 100%, 75% and 100%, respectively, of mice for more than 30 days after challenge. In contrast, injection of necrotic tumor cells led to protection of no more than 0-30%. Prolonged tumor-free survival was also observed in mice after vaccination with irradiated B16 cells. In vivo protection experiments correlated very well with in vitro cytotoxicity assays. Immunohistochemical analysis of the vaccine site showed a strong CD4(+) and CD8(+) T-cell response after injection of apoptotic cells, which was accompanied by the presence of dendritic cells. In contrast, necrotic cell vaccines attracted a strong local macrophage response. Our data clearly demonstrate that only apoptotic tumor cell vaccines induce a potent antitumor immune response.

Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes.

Recombinant soluble MHC molecules are widely used for visualization, activation and inhibition of antigen-specific immune responses. Using a genetic approach, we have generated two novel peptide-beta2-microglobulin-MHC constructs. We have linked the MHC molecule with the peptide of interest, without limiting the recognition by the cognate TCR. This molecule can also be joined with the IgG heavy chain resulting in a dimeric MHC-Ig fusion protein. These molecules bind antigen-specific T cells with high specificity and sensitivity, therefore, providing a valuable tool for detection as well as enrichment of antigen-specific T cells.